Saving Jack Kerouac[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] His tidily rhyming names perhaps destined him for fame. While Jack Kerouac’s work and popularity were before my time, his cultural and literary restlessness assure him […]
Articles
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
$RARE Ultragenyx (RARE) shares drop as muscle-disease drug study fails (8/22) Ultragenyx Pharmaceutical Inc. RARE,...
Ultragenyx ($RARE) mentioned by Citigroup as one of six next takeover targets in the next 12-18 months after Relypsa and...
Ultragenyx $RARE has presented positive clinical data from a late stage trial of mucopolysaccharidosis type 7, among man...
Ultragenyx $RARE started at overweight by Piper Jaffray, with PT $70. Long $RARE. Strong M&A candidate. HN score ...
Takeda investing in and partnering with Ultragenyx $RARE. Among my favorite holdings. HN score A. I have big paper profi...
Despite 100 percent run up this year, Stifel Nicolaus (finger on the pulse!) initiates UltraGenyx $RARE as buy with $125...
JMP initiates coverage of Ultragenyx $RARE this am with, buy recommendation and $119 PT. Long $RARE....great ultra-o...
Biotech set for strong open. Love the news out of Ultragenyx $RARE. Shaping up to be my fastest 100 percent gainer of al...
I cannot share the market's enthusiasm for BioMarin $BMRN and its dwarfism remedy. There is no evidence whatsoever that ...
Ultragenyx (RARE) should be on the move up today. Very nice positive phase 2 interim data with x-linked hypophosphat...
A reminder that I have been long in Ultragenyx ($RARE) since the beginning of the year. This stock is up 33 percent for...